BerGenBio ASA (OSTO:BGBIOO)

kr 9.999 0 (0%) Market Cap: 328.96 Mil Enterprise Value: 154.11 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 35/100

Q3 2024 Bergenbio ASA Earnings Call Transcript
Nov 13, 2024

kr344.5

Earnings
Q2 2024 Bergenbio ASA Earnings Call Transcript
Aug 21, 2024

kr344.5

Earnings
Q1 2024 Bergenbio ASA Earnings Call Transcript
May 29, 2024

kr344.5

Earnings
Q3 2023 Bergenbio ASA Earnings Call Transcript
Nov 14, 2023

kr344.5

Earnings
Q2 2023 Bergenbio ASA Earnings Call Transcript
Aug 23, 2023

kr344.5

Earnings
Q4 2022 Bergenbio ASA Earnings Call Transcript
Feb 16, 2023

kr344.5

Earnings
Q3 2022 Bergenbio ASA Earnings Call Transcript
Nov 15, 2022

kr383.31

Earnings
Q2 2022 Bergenbio ASA Earnings Call Transcript
Aug 23, 2022

kr644.86

Earnings
Q1 2022 Bergenbio ASA Earnings Call Transcript
May 24, 2022

kr775.25

Earnings
Bergenbio ASA Strategy Update Transcript
May 04, 2022
Q4 2021 Bergenbio ASA Earnings Call Transcript
Feb 16, 2022

kr903.61 (-13.54%)

Earnings
Q3 2021 Bergenbio ASA Earnings Call Transcript
Nov 16, 2021

kr1004.58

Earnings
Q2 2021 Bergenbio ASA Earnings Call Transcript
Aug 17, 2021

kr1135.48 (-6.83%)

Earnings
Q1 2021 Bergenbio ASA Earnings Call Transcript
May 19, 2021

kr1197.38 (-18.79%)

Earnings
Bergenbio ASA to Discuss Top Line Data From Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients Call Transcript
May 18, 2021
Q4 2020 Bergenbio ASA Earnings Call Transcript
Feb 10, 2021

kr1674.3

Earnings
Q3 2020 Bergenbio ASA Earnings Call Transcript
Nov 17, 2020

kr1420.62 (-5.08%)

Earnings
Q2 2020 Bergenbio ASA Earnings Call Transcript
Aug 18, 2020

kr1785.92

Earnings
Q1 2020 Bergenbio ASA Earnings Call Transcript
May 19, 2020

kr2029.46 (-7.41%)

Earnings
Q4 2019 Bergenbio ASA Earnings Call Transcript
Feb 11, 2020

kr953.84 (+7.67%)

Earnings

Q2 2023 Bergenbio ASA Earnings Call Transcript

Aug 23, 2023 / 08:45AM GMT

Release Date Price: kr344.5

Transcript

Martin Olin

BerGenBio ASA - CEO

Good morning, and welcome. I'm Martin Olin, the CEO of BerGenBio. I'm pleased to provide you with our Q2 2023 report. Just remind the audience about the formalities.

So BerGenBio in a nutshell, we consider ourselves to be the world leader in AXL biology. And we know that AXL biology is important. It's known to play a key role in the progression of several diseases, including cancer, respiratory diseases, and fibrosis.

We have two proprietary, which means our own, clinical stage program: bemcentinib, a small molecule, which is our lead program; and tilvestamab, a monoclonal antibody. In multiple Phase 2 trials, we have shown that the relevance of bemcentinib is quite important as it confers to clinical benefits in non-small-cell lung cancer, in AML, in MDS, and mesothelioma. And the data all points to the same direction, that bemcentinib actually leads to an increased progression-free survival, but also overall survival for these patients across these diseases. So this is quite interesting.

We are, however, focusing the development of

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.